Hashimoto K, Haruno A, Matsuzaki T, Sugiyama A, Akiyama K
Department of Pharmacology, Yamanashi Medical College, Japan.
Cardiovasc Drugs Ther. 1991 Aug;5 Suppl 4:805-17. doi: 10.1007/BF00120829.
In order to compare and clarify the effects of various antiarrhythmic drugs when given as monotherapy, we reevaluated our previous data on antiarrhythmic drugs and recalculated antiarrhythmic plasma concentrations of drugs for several canine arrhythmia models. We used three spontaneously occurring arrhythmias: a) digitalis-, b) two-stage coronary ligation-, and c) adrenaline-induced arrhythmias. All antiarrhythmic drugs of class I suppressed digitalis arrhythmia, and, except for lidocaine, also suppressed coronary ligation arrhythmia. Class II antiarrhythmic drugs, beta blockers, and class IV antiarrhythmic drugs, Ca antagonists, had common features of effectiveness and suppressed adrenaline arrhythmia in relatively low concentrations. Class III drugs were not effective on these three arrhythmias. Differences among the antiarrhythmic effects of class I drugs could not be explained by their subclassification based either on action potential duration or kinetic properties of dissociation or association with Na channels. New triggered arrhythmia models in vivo and in vitro canine hearts were developed, and drug effects were not the same as those on the three spontaneously occurring arrhythmia models.
为了比较和阐明各种抗心律失常药物单药治疗时的效果，我们重新评估了之前关于抗心律失常药物的数据，并重新计算了几种犬心律失常模型中药物的抗心律失常血浆浓度。我们使用了三种自发性心律失常：a）洋地黄引起的，b）两阶段冠状动脉结扎引起的，以及c）肾上腺素诱导的心律失常。所有I类抗心律失常药物均能抑制洋地黄心律失常，除利多卡因外，也能抑制冠状动脉结扎心律失常。II类抗心律失常药物（β受体阻滞剂）和IV类抗心律失常药物（钙拮抗剂）具有共同的有效性特征，且在相对较低浓度下就能抑制肾上腺素心律失常。III类药物对这三种心律失常无效。I类药物抗心律失常作用的差异无法用基于动作电位持续时间或与钠通道解离或结合的动力学特性的亚分类来解释。我们建立了体内和体外犬心脏新的触发心律失常模型，药物作用与三种自发性心律失常模型不同。
